{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:04:44Z","timestamp":1793862284475,"version":"4.6.1"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Cushing disease (CD) is caused by a pituitary tumor which oversecretes adrenocorticotropic hormone (ACTH). It is a serious endocrine disease associated with increased mortality and impaired quality of life. The management of CD remains challenging. Although transsphenoidal surgery is the treatment of choice in most cases, in approximately half of CD patients, second or third-line treatment options are needed. Currently, new medical therapies are available which target adrenal steroidogenesis, pituitary somatostatin and dopamine receptors, and glucocorticoid receptors. Selection of which medication to use should be individualized and is determined by many factors including severity of the disease, possible side effects, patients preferences and local availability. The aim of this article is to describe currently available medical therapy to help clinicians individualize the treatment options in the context of recently updated Pituitary Society recommendations.<\/jats:p>","DOI":"10.3389\/fendo.2022.1060884","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T06:08:31Z","timestamp":1669961311000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Individualized medical treatment options in Cushing disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Aleksandra","family":"Gilis-Januszewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bogus\u0142awska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Rzepka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Ziaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Hubalewska-Dydejczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/j.1550-8528.1994.tb00097.x","article-title":"The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). 1932","volume":"2","author":"Cushing","year":"1994","journal-title":"Obes Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of cushing\u2019s syndrome: An endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of cushing\u2019s disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0272","article-title":"The European registry on cushing\u2019s syndrome: 2-year experience. baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing\u2019s syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S44336","article-title":"Cushing\u2019s syndrome: Epidemiology and developments in disease management.","volume":"7","author":"Sharma","year":"2015","journal-title":"Clin Epidemiol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02524","article-title":"Overall and disease-specific mortality in patients with cushing disease: A Swedish nationwide study","volume":"104","author":"Ragnarsson","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in cushing\u2019s disease: Is it worth a try","volume":"99","author":"Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"A515","DOI":"10.1210\/jendso\/bvab048.1053","article-title":"Metyrapone treatment in endogenous cushing\u2019s syndrome: Results at week 12 from PROMPT, a prospective international multicenter, open-label, phase III\/IV study","volume":"5","author":"Nieman","year":"2021","journal-title":"J Endocrine Soc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the medical treatment of cushing\u2019s syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating cushing \u2019 s Syndrome: A retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00648","article-title":"Medical treatment of cushing\u2019s disease: An overview of the current and recent clinical trials","volume":"11","author":"Pivonello","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.1055","article-title":"Osilodrostat is an effective and well-tolerated treatment for cushing\u2019s disease (CD): Results from a phase III study with an upfront, randomized, double-blind, placebo-controlled phase (LINC 4)","volume":"5","author":"Gadelha","year":"2021","journal-title":"J Endocrine Soc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","article-title":"Efficacy and safety of once-monthly pasireotide in cushing\u2019s disease: a 12 month clinical trial","volume":"6","author":"Lacroix","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0897-z","article-title":"Effectiveness of medical treatment for cushing\u2019s syndrome: a systematic review and meta-analysis","volume":"21","author":"Broersen","year":"2018","journal-title":"Pituitary"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0662","article-title":"Cabergoline for cushing\u2019s disease: A large retrospective multicenter study","volume":"176","author":"Ferriere","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11b-hydroxylase inhibitor, normalizes urinary cortisol in patients with cushing\u2019s disease: results from a multicenter, proofof-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14551","article-title":"Osilodrostat in cushing's disease: The risk of delayed adrenal insufficiency should be carefully monitored","volume":"5","author":"Castinetti","year":"2022","journal-title":"Clin Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1105743","article-title":"A 12-month phase 3 study of pasireotide in cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1843","article-title":"Changes in plasma ACTH levels and corticotroph tumor size in patients with cushing\u2019s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone","volume":"99","author":"Fleseriu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(90)90010-a","article-title":"Effect of ketoconazole on plasma sex hormones, lipids, lipoproteins, and apolipoproteins in hyperandrogenic women","volume":"39","author":"Cedeno","year":"1990","journal-title":"Metabolism"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-5-1426","article-title":"Infusion of low dose etomidate: correction of hypercortisolemia in patients with cushing\u2019s syndrome and dose-response relationship in normal subjects","volume":"70","author":"Schulte","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, phase II study in cushing\u2019s disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2015.05.004","article-title":"Osilodrostat (LCI699), a potent 11\u03b2-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats","volume":"286","author":"Li","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3967\/0895-3988.2013.07.013","article-title":"Ketoconazole associated hepatotoxicity: A systematic review and meta-analysis","volume":"26","author":"Yan","year":"2013","journal-title":"BioMed Environ Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-01268-2","article-title":"Treatment of cushing\u2019s syndrome with osilodrostat: practical applications of recent studies with case examples","volume":"24","author":"Fleserieu","year":"2022","journal-title":"Pituitary."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000013148","article-title":"Invasive ACTH-secreting pituitary macroadenoma in remission after transsphenoidal resection","volume":"97","author":"Zhuang","year":"2018","journal-title":"Med (United States)."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0893-3","article-title":"Endoscopic vs. microscopic transsphenoidal surgery for cushing\u2019s disease: a systematic review and meta-analysis","volume":"21","author":"Broersen","year":"2018","journal-title":"Pituitary"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/1203475415574970","article-title":"The rise and fall of oral ketoconazole","volume":"19","author":"Gupta","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110903","article-title":"Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes","volume":"71","author":"Loose","year":"1983","journal-title":"J Clin Invest."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1159\/000314292","article-title":"Medical treatment of cushing\u2019s syndrome: Adrenal-blocking drugs and ketaconazole","volume":"92","author":"Feelders","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.amjmed.2015.10.029","article-title":"Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status","volume":"129","author":"Re","year":"2016","journal-title":"Am J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-18-8-906","article-title":"Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 \u03b2-hydroxylation","volume":"18","author":"Liddle","year":"1958","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021032","article-title":"Clinical and endocrine responses to pituitary radiotherapy in pediatric cushing's disease: an effective second-line treatment","volume":"88","author":"Storr","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01263-7","article-title":"Levoketoconazole in the treatment of patients with endogenous cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)","author":"Pivonello","year":"2022","journal-title":"Pituitary."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-1014","article-title":"Therapy of endocrine disease: steroidogenesis enzyme inhibitors in cushing\u2019s syndrome","volume":"172","author":"Daniel","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejogrb.2012.12.015","article-title":"The medical management of cushing's syndrome during pregnancy","volume":"168","author":"Lim","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0742-1","article-title":"Updates on the role of adrenal steroidogenesis inhibitors in cushing\u2019s syndrome: a focus on novel therapies","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.903545","article-title":"Metyrapone versus osilodrostat in the short-term therapy of endogenous cushing's syndrome: Results from a single center cohort study","volume":"13","author":"Detomas","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0208","article-title":"Differences in the spectrum of steroidogenic enzyme inhibition between osilodrostat and metyrapone in ACTH-dependent cushing syndrome patients","volume":"187","author":"Bonnet-Serrano","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-197603000-00035","article-title":"Etomidate: an ultrashort-acting nonbarbiturate agent for anesthesia induction","volume":"55","author":"Gooding","year":"1976","journal-title":"Anesth Analg"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1984.tb08885","article-title":"Mortality amongst multiple trauma patients admitted to an intensive therapy unit","volume":"39","author":"Watt","year":"1984","journal-title":"Anaesthesia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1177\/20420188211058583","article-title":"Pharmacological management of severe cushing's syndrome: the role of etomidate","volume":"13","author":"Pence","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1249629","article-title":"Etomidate unmasks intraadrenal regulation of steroidogenesis and proliferation in adrenal cortical cell lines","volume":"42","author":"Hahner","year":"2010","journal-title":"Hormone Metab Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0274","article-title":"Etomidate in the management of hypercortisolaemia in cushing's syndrome: a review","volume":"167","author":"Preda","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropindependent cushing\u2019s syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-0380","article-title":"Etomidate infusion at low doses is an effective and safe treatment for severe cushing\u2019s syndrome outside intensive care unit","volume":"183","author":"Constantinescu","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.9.7870","article-title":"Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic cushing\u2019s syndrome","volume":"86","author":"Krakoff","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/ALN.0b013e3181ff72b5","article-title":"Clinical and molecular pharmacology of etomidate","volume":"114","author":"Forman","year":"2011","journal-title":"Anesthesiology"},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1002\/9781119031659.ch16","article-title":"Pituitary tumor treatment with somatostatin analogues","volume-title":"Somatostatin analogues: From research to clinical practice","author":"Hubalewska-Dydejczyk","year":"2015"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1159\/000314352","article-title":"Medical treatment of cushing\u2019s disease: somatostatin analogues and pasireotide","author":"Pedroncelli","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S44336","article-title":"Cushing\u2019s syndrome: Epidemiology and developments in disease management","volume":"7","author":"Sharma","year":"2015","journal-title":"Clin Epidemiol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200310000-00005","article-title":"Crooke\u2019s cell adenoma of the pituitary: An aggressive variant of corticotroph adenoma","volume":"27","author":"George","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0979","article-title":"Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas","volume":"176","author":"Lasolle","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz211","article-title":"Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas-a German survey","volume":"105","author":"Elbelt","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2006.105.4.621","article-title":"Long-term response of pituitary carcinoma to temozolomide. report of two cases","volume":"105","author":"Fadul","year":"2006","journal-title":"J Neurosurg"},{"key":"B62","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2018.0011","article-title":"Temozolomide therapy for aggressive pituitary crooke's cells corticotropinoma causing cushing's disease: A case report with literature review","volume":"10","author":"Gilis-Januszewska","year":"2018","journal-title":"Endokrynol. Pol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ccr3.39","article-title":"Long-term remission in an aggressive crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide","volume":"2","author":"Asimakopoulou","year":"2014","journal-title":"Clin Case Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-019-09534-8","article-title":"Aggressive pituitary tumors in the young and elderly","volume":"21","author":"Tatsi","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0b013e318230ac63","article-title":"O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas","volume":"70","author":"Salehi","year":"2012","journal-title":"Neurosurgery"},{"key":"B67","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11060-017-2520-y","article-title":"Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: A multicenter study","volume":"135","author":"Cohen-Inbar","year":"2017","journal-title":"J Neurooncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40842-020-00105-4","article-title":"Clinical management of patients with cushing syndrome treated with mifepristone: consensus recommendations","volume":"6","author":"Brown","year":"2020","journal-title":"Clin Diabetes Endocrinol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-00188","article-title":"Mifepristone increases thyroid hormone requirements in patients with central hypothyroidism: A multicenter study","volume":"3","author":"Guarda","year":"2019","journal-title":"J Endocr Soc"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13818","article-title":"Mifepristone in the treatment of the ectopic adrenocorticotropic hormone syndrome","volume":"89","author":"Wannachalee","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.793262","article-title":"Glucocorticoid receptor antagonism upregulates somatostatin receptor subtype 2 expression in ACTH-producing neuroendocrine tumors: New insight based on the selective glucocorticoid receptor modulator relacorilant","volume":"12","author":"Pivonello","year":"2022","journal-title":"Front Endocrinol"},{"key":"B72","article-title":"PubChem compound summary for CID 73051463","year":"2022","journal-title":"Relacorilant"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101381","article-title":"Cushing\u2019s syndrome: Treatment and new therapeutic approaches","volume":"34","author":"Ferriere","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.389","article-title":"Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: An adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study","volume":"7","author":"Hunt","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1731","article-title":"An In vitro and In vivo evaluation of the effect of relacorilant on the activity of cytochrome P450 drug metabolizing enzymes","volume":"61","author":"Custodio","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.662865","article-title":"Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with cushing syndrome: Results from a prospective, open-label phase 2 study","volume":"12","author":"Pivonello","year":"2022","journal-title":"Front Endocrinol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2015.02.032","article-title":"Discovery and development of seliciclib. how systems biology approaches can lead to better drug performance","volume":"202","author":"Khalil","year":"2015","journal-title":"J Biotechnol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac588","article-title":"Treatment of cushing\u2019s disease with pituitary-targeting seliciclib","volume":"10","author":"Liu","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.60842","article-title":"The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas","volume":"11","author":"Dai","year":"2020","journal-title":"Front Endocrinol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001532","article-title":"Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study","volume":"8","author":"Majd","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01347","article-title":"Marked response of a hypermutated acth-secreting pituitary carcinoma to ipilimumab and nivolumab","volume":"103","author":"Lin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B82","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","article-title":"Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab","volume":"31","author":"Caccese","year":"2020","journal-title":"Anticancer Drugs"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030088","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature","volume":"10","author":"Duhamel","year":"2020","journal-title":"J Pers Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0536","article-title":"Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH dependent cushing's syndrome","volume":"96","author":"Kamenick\u00fd","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in cushing's disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N Engl J Med"},{"key":"B86","article-title":"Prospective phase II study (CAPACITY) of pasireotide monotherapy or in combination with cabergoline in patients with cushing's disease","author":"Feelders","year":"2017","journal-title":"Poster Presented at ENDO Orlando FL"},{"key":"B87","doi-asserted-by":"publisher","first-page":"P693","DOI":"10.1530\/endoabs.81.P693","article-title":"Multimodal treatment including temozolomide (TMZ) and pasireotide for aggressive, giant silent corticotroph PiTNET in a young patient","volume":"81","author":"Bogus\u0142awska","year":"2022","journal-title":"Endocrine Abstracts"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-022-00397-4","article-title":"Cushing\u2019s syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia","volume":"9","author":"Dzialach","year":"2022","journal-title":"Hormones (Athens)."},{"key":"B89","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1530\/EDM-21-0071","article-title":"Synertistic cortisol suppression by ketoconazole-osilodrostat combination therapy","volume":"2021","author":"Amodru","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1060884\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T06:08:36Z","timestamp":1669961316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1060884\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":89,"alternative-id":["10.3389\/fendo.2022.1060884"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1060884","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"article-number":"1060884"}}